The Consortium continues to increase its membership reflecting the urgent need to develop new products for Alzheimer’s disease. As of September 2016, there are over 60 people registered on the mailing list representing approximately 40 companies. Please continue to introduce new members and/or companies that may be interested and make suggestions for ideas and events for the AABC to better serve its membership. For future issues of this Newsletter please let us know if there is content that you would like to us to include.

For those of you not familiar with the AABC, we encourage you to get involved in 2016 / 2017 by attending one of our events. Please email Charles Stacey (cstacey@accerapharma.com), Kira Sheinerman (ksheinerman@diamirbio.com) or Jim Hendrix (jhendrix@alz.org) to be added to the membership list mailing list.

Mission of the AABC

The mission of the AABC is to advance Alzheimer’s disease research and innovation in small/medium-sized biotechnology, diagnostics, medical device, and contract research organizations.

The AABC works to achieve their mission by working in areas of common interest in a pre-competitive space to advance both the field of Alzheimer’s research and the member company’s goals. The AABC member companies provide leadership and direction to the organizations areas of focus that include but are not limited to: Collaborations, Recognition & Visibility and Knowledge and Information Sharing.

News from AABC members and growth AD companies

June 14, 2016: French CRO SynAging SAS (www.synaging.com) has finalized its AD and PD in vitro assay development on human iPS cell derived neuronal culture. The Parkinson’s disease model for neurodegeneration is induced in the fully differentiated human neuronal culture by minute amounts of SynAging’s α-synuclein fibrils, or α-synuclein oligomers. Before the Alzheimer’s model for neurodegeneration using amyloid-β oligomers had been released. The human neuronal cultures were enabled by collaboration with MTI-GlobalStem (Gaithersburg, MD, USA) providing the human induced pluripotent stem (iPS) cells and neuronal differentiation kit to enable reproducible cultures for testing. Translation towards the clinic is facilitated by SynAging’s AD and PD models in mice.

SynAging also presented Posters at AAIC 2016 in Toronto on in vitro and in vivo models of AD
and PD. Copies of these posters can be found on their website: www.synaging.com in the news section for download. They have also have posted a list of meetings that SynAging is attending there. Interested people can follow SynAging on LinkedIn:https://www.linkedin.com/company/synaging-sas

T3D Therapeutics Announces Presentation of Phase 2a Preliminary Results of T3D-959 in Alzheimer’s Subjects at the 2016 Alzheimer’s Association International Conference

An investigational new drug, T3D-959, elicited rapid improvement in ADAS-cog11 cognitive tests in 53% of subjects with mild to moderate Alzheimer’s disease in an exploratory, open label Phase 2a study, with average group improvements sustained at follow-up, 7 days postdosing. A subset of patients (31%) in the study, 50% of whom had moderate disease severity, had an average improvement in ADAS-cog11 of 6.03 points at follow-up.

For more information, please visit http://www.t3dtherapeutics.com/.

Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease

Former NeuroPhage Pharmaceuticals advances novel treatment for protein misfolding diseases: NPT088 shown to be safe and well-tolerated in Phase 1a study

CAMBRIDGE, Mass., Sept. 7, 2016 – Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that it has initiated a Phase 1b clinical trial evaluating NPT088, its lead development candidate for Alzheimer’s disease. In a separate announcement also released today, the former NeuroPhage Pharmaceuticals reported that it has secured $47 million in new financing and relaunched under the name Proclara Biosciences as a clinical-stage company. For more information, please visit proclarabio.com.

Proclara Biosciences Announces $47 Million in New Investment to Support the Development of Product Candidates in Alzheimer’s, Parkinson’s and Other Diseases

CAMBRIDGE, Mass., Sept. 7, 2016 – Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that the company has secured $47 million in a Series E financing to support the development of product candidates for Alzheimer’s, Parkinson’s and other diseases. Additionally, the former NeuroPhage Pharmaceuticals announced that it has changed its name to Proclara Biosciences, marking its evolution into a clinical stage company. In a separate announcement released today, Proclara also reported that it has initiated a Phase 1b clinical trial of its lead product candidate, NPT088, for Alzheimer’s disease. For more information, please visit proclarabio.com.

Schedule of Events for Q3 and Q4 2016

1. Webinar: SBIR/STTR funding for Alzheimer’s Disease

   Date: November 2, 2016, 11 am ET / 8 am PT
Genzyme, Lift Labs and many other life sciences companies were started with SBIR funding. Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are non-dilutive, peer-reviewed, competitive funding opportunities designed to foster scientific innovation through cooperative research and development. This webinar will focus on SBIR and STTR opportunities in Alzheimer’s disease and related fields. Small companies need funding and expert advice and SBIR/STTR programs need high quality proposals!

**Panelists:**

**Lorenzo M. Refolo PhD**  
Program Director  
Alzheimer’s Drug Development Program  
National Institute on Aging

**Sharon Rosenzweig-Lipson, PhD**  
Vice President of Research and Development  
AgeneBio

**Kira Sheinerman, PhD**  
Chief Executive Officer  
DiamiR

**Moderator:**

**James Hendrix, PhD**  
Director, Global Science Initiatives  
Alzheimer's Association

**JOIN WEBEX MEETING**

https://alz-org.webex.com/alz-org/j.php?MTID=m3b05f49b6f5e21ff38b2300d8dbe47fc  
Meeting number: 743 899 110

**JOIN BY PHONE**

Call-in toll-free number: 1-866-316-2054 (US)  
Call-in number: 1-763-391-6884 (US)  
Show global numbers:  
https://www.tcconline.com/offSite/OffSiteController.jpf?cc=4428596748  
Conference Code: 442 859 6748

2. **AABC Breakfast Event during CTAD 2016, San Diego, USA**

**Date:** December 9, 2016, 7 am PT  
**Location:** Marina Kitchen Dining Room, Marriott Marquis San Diego Marina  
333 W Harbor Drive, San Diego, CA

3. **Webinar: Fundraising for Alzheimer’s Disease companies**

**Date:** To be scheduled  
**Topics:** Is the investor environment getting better or worse?  
Top tips for companies looking to fund raise this year  
Lessons in investor selection
Most common areas of focus in investor due diligence

**Panelists:** To include companies that have recently raised funds and investors that have recently invested in AD

**Moderator:** Charles Stacey – Co-Chair of the AABC and CEO, Accera, Inc.

4. **Webinar: Success stories in Alzheimer’s Disease**

**Date:** To be scheduled

**Topics:** Specific successes that AD companies have experienced

**Panelists:** TBC

**Moderator:** Kira Sheinerman – Co-Chair of the AABC and CEO, DiamiR Biosciences

**AABC Collaboration**

**Job postings**

M3 Biotechnology is searching for a CMC (small molecule) consultant and clinical consultant with international experience preferred. Contact Leen Kawas, Ph.D., CEO & President for more information or to make a referral.

To post your job listings in future newsletters, please inform Charles Stacey on: cstacey@accerapharma.com

**General postings to the AABC membership**

**Member Company Publication:**

Proclara Biosciences (Formerly Neurophage) recently published:

**NPT088 reduces both amyloid-b and tau pathologies in transgenic mice**


**Member Company Information:**

BrainBits® isolates Dorsal Root Ganglia (“DRGs”) and Spinal Cords from rats and mice and delivers them directly to your facility. Tissues arrive suspended in media, ready to be used immediately. Never frozen, these tissues are not exposed to the harsh freeze/thaw cycles associated with cryogenically stored cells. This leads to significantly higher viability. Store BrainBits® tissue in your refrigerator at 4°C and use within one week of receipt for best results. For more information see: www.brainbitsllc.com
To post any general postings in future newsletters, please inform Charles Stacey on: cstacey@accerapharma.com

Past Events

1. **AABC Networking Event at the Alzheimer’s Association International Conference (AAIC)**  
   Monday, July 25th 2016, 7-9 pm  
   Parkdale Room, Delta Hotel, 75 Lower Simcoe Street, Toronto  
   This event was well attended by AABC and ISTAART members. It provided an opportunity for AABC members to meet and network with scientists who are AABC members and with those who are just interested in growing companies working in the Alzheimer space. We hope that this event enabled the attendees to expand their reach and network.

   Stay tuned for other events and updates.

   **Best wishes,**

   **Jim Hendrix, Charles Stacey and Kira Sheinerman**